Merck & Company Inc. Common Stock (new) (MRK)
Stock · NYSE · Health Care
$148.35as of 8/28/2026
Price chart
Open in TradingViewActive signals
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 73,000
- Website
- www.merck.com/
Fundamentals
- 1-day range
- $145.75$149.01
- Market cap
- $315.57B
- P/E (trailing)
- 103.86
- P/E (forward)
- 15.55
- EPS (trailing)
- $1.25
- Dividend yield
- 2.87%
- Beta
- 0.22
- Avg. volume
- 10.94M
- Ex-dividend date
- September 15, 2026
- Dividend pay date
- October 7, 2026
How Merck & Company Inc. Common Stock (new) Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Merck & Company Inc. Common Stock (new) Competitors
Chosen by industry and closest market cap.
- MRKMerck & Company Inc. Common Stock (new)$148.32▼ 0.82%Market cap $315.57BP/E 103.86$77.58$156.92
- NVSNovartis AG Common Stock$153.79▼ 0.56%Market cap $293.23BP/E 21.95$96.03$131.5
- AZNAstraZeneca PLC Ordinary Shares$162.69▼ 1.11%Market cap $244.97BP/E 23.44$10,784$15,730
- NVONovo Nordisk A/S Common Stock$45.6▼ 1.43%Market cap $208.51BP/E 11.40$224.25$409.95
- ABBVAbbVie Inc. Common Stock$255.56▼ 1.01%Market cap $433.04BP/E 70.24$190.75$267.47
- ABTAbbott Laboratories Common Stock$112.42▲ 0.74%Market cap $185.36BP/E 35.52$81.97$137.49
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $142.66BP/E 35.19$23.58$28.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MRK Merck & Company Inc. Common Stock (new) | $315.57B | 103.86 | $148.32 | ▼ 0.82% | $77.58$156.92 |
| NVS Novartis AG Common Stock | $293.23B | 21.95 | $153.79 | ▼ 0.56% | $96.03$131.5 |
| AZN AstraZeneca PLC Ordinary Shares | $244.97B | 23.44 | $162.69 | ▼ 1.11% | $10,784$15,730 |
| NVO Novo Nordisk A/S Common Stock | $208.51B | 11.40 | $45.6 | ▼ 1.43% | $224.25$409.95 |
| ABBV AbbVie Inc. Common Stock | $433.04B | 70.24 | $255.56 | ▼ 1.01% | $190.75$267.47 |
| ABT Abbott Laboratories Common Stock | $185.36B | 35.52 | $112.42 | ▲ 0.74% | $81.97$137.49 |
| PFE Pfizer Inc. Common Stock | $142.66B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR SurgicalYahoo · 8/22/2026
- Benzinga Bulls and Bears: Ross, Moderna, WebullBenzinga · 8/22/2026
- ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’Yahoo · 8/22/2026
- 3 American Stocks Showing the Same Setup That Sent Moderna Up 177%Yahoo · 8/21/2026
- Moderna, Merck Cancer Vax Gives HopeYahoo · 8/21/2026
- SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data AnticipationYahoo · 8/21/2026
- Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s MarketYahoo · 8/21/2026
- Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats UpYahoo · 8/21/2026
- Why Is Tempus AI Stock Gaining Thursday?benzinga · 8/20/2026
Insider Activity
Insider Actions →- Chirfi Guindo · August 13, 2026 · Sale10.0K @ $135
- Jennifer Zachary · August 12, 2026 · Option Exercise13.4K @ $84.71
- Jennifer Zachary · August 12, 2026 · Option Exercise41.5K @ $117.89
- Jennifer Zachary · August 12, 2026 · Sale80.3K @ $133.46
- Richard R. DeLuca · August 12, 2026 · Sale600 @ $132.04
- Richard R. DeLuca · August 12, 2026 · Sale11.1K @ $131.61
- Richard R. DeLuca · August 11, 2026 · Sale5.4K @ $132.35
- Richard R. DeLuca · August 11, 2026 · Sale7.4K @ $131.33
- Richard R. DeLuca · August 10, 2026 · Sale20.8K @ $130.43
- Chirfi Guindo · August 6, 2026 · Sale15.0K @ $131
- Richard R. DeLuca · August 6, 2026 · Sale300 @ $131.02
- Richard R. DeLuca · August 6, 2026 · Sale4.9K @ $130.23
- Richard R. DeLuca · August 6, 2026 · Sale805 @ $131.02
- David R. Maraldo · August 5, 2026 · Option Exercise2.7K @ $84.71
- David R. Maraldo · August 5, 2026 · Option Exercise9.7K @ $87.1
Institutional Ownership
March 31, 2026
- Total shares held
- 1.82B
- Total value held
- $209.80B
- Institutional holders
- 3703
- Unknown225.93M
- Unknown160.99M
- Unknown119.33M
- Unknown84.31M
- Unknown59.56M
- Unknown49.77M
- Unknown47.63M
- Unknown44.52M
- Unknown30.77M
- Unknown27.09M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
MRK Among Dow Jones Movers as Ebola Emergency Declared. Merck shares were active in today's Dow Jones session after the World Health Organization confirmed the Ebola outbreak in the Democratic Republic of Congo still meets the criteria for a Public Health Emergency of International Concern. Merck has been developing Ebola treatments, including the antiviral mAb114, which received FDA approval in 2019. The company was also flagged in a list of healthcare stocks with notable options activity, adding to intraday interest. With shares trading near $118.76 support and a trailing P/E of 103.9, the stock remains well above its 52-week low of $77.58.